Eris Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kaushal Kamleshbhai Shah, on behalf of all promoters and the promoter group of Eris Lifesciences, has filed the annual declaration under SEBI's Regulation 31(4) of the Takeover Regulations for the financial year ended March 31, 2025. The promoters collectively hold 7,46,83,744 equity shares, representing about 54.85% of the company's equity share capital. The key confirmation in this filing is that the promoters have not created any new encumbrance (pledge, lien, or other security) on their shares during the year, other than what was already disclosed earlier. This is a routine annual compliance requirement and not a new corporate action.
This is a standard regulatory filing with no material impact on the stock price or shareholders. Investors can take comfort that promoter holdings remain free of fresh pledges or encumbrances, indicating continued confidence and no immediate liquidity stress for the promoter group.